There are 594 resources available
82P - A retrospective real-world evidence study of MTAP status and clinical outcomes in patients with advanced non-small cell lung cancer
Presenter: Adrian Sacher
Session: Poster Display session
83P - Efficacy and safety of lorlatinib in patients with ALK+ metastatic non-small cell lung cancer (mNSCLC) previously treated with an ALK inhibitor: Results from a phase IV study
Presenter: Alessandra Bearz
Session: Poster Display session
84P - High prevalence of actionable driver alterations in lung cancer patients with germline MUTYH mutations
Presenter: Zhaohui Arter
Session: Poster Display session
85P - Phase I results from the phase I/II POTENT trial of tepotinib and pembrolizumab in non-small cell lung cancer (NSCLC)
Presenter: Kira-Lee Koster
Session: Poster Display session
86P - Diagnosis and treatment patterns in adults with metastatic non-small cell lung cancer with BRAF V600E mutation in clinical practice: An international ambispective real-world study (OCTOPUS)
Presenter: Céline Mascaux
Session: Poster Display session
87P - Genomic alterations and resistance mechanisms in ALK-rearranged non-small cell lung cancer: Insights from NGS profiling and clinical outcomes
Presenter: Paolo Ambrosini
Session: Poster Display session
88P - Real-world occurrence of early-onset pulmonary events with brigatinib for advanced ALK+ NSCLC
Presenter: Maximilian Hochmair
Session: Poster Display session
89P - Clinical characteristics, treatment patterns, and outcomes of first-line brigatinib in patients with advanced ALK+ NSCLC: A multinational real-world study
Presenter: Sharmistha Ghosh
Session: Poster Display session
90P - Efficacy of subsequent therapy following the progression of crizotinib in advanced ROS1+ NSCLC in real word setting
Presenter: Zihua Zou
Session: Poster Display session
91P - Intracranial efficacy of crizotinib in advanced ROS1+NSCLC in real-world setting
Presenter: Zihua Zou
Session: Poster Display session